The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
复制标题
DOI:
10.1007/s10552-021-01450-0
复制
发表时间:
2021-09
期刊:
影响因子:
--
通讯作者:
Markides K
中科院分区:
文献类型:
--
作者:
Lopez DS;Huang D;Tsilidis KK;Canfield S;Khera M;Baillargeon JG;Kuo YF;Peek MK;Platz EA;Markides K
Previous studies have reported conflicting results in the associations of testosterone replacement therapy (TTh) and statins use with prostate cancer (PCa). However, the combination of these treatments with PCa stage and grade at diagnosis and prostate cancer-specific mortality (PCSM) and by race/ethnicity remains unclear. We identified non-Hispanic White (NHW, N=58576), non-Hispanic Black (NHB, N=9703) and Hispanic (N=4898) men diagnosed with PCa in SEER-Medicare data 2007–2011. Pre-diagnostic prescription of TTh and statins was ascertained for this analysis. Multivariable-adjusted logistic and Cox proportional hazards models were used to evaluate the association of TTh and statins use with PCa stage and grade and PCSM. 22.5% used statins alone, 1.2% used TTh alone, and 0.8% used both. TTh and statins were independently, inversely associated with PCa advanced stage and high grade. TTh plus statins was associated with 44% lower odds of advanced-stage PCa (OR = 0.56, 95% CI: 0.35 – 0.91). As expected, similar inverse associations were present in NHWs as the overall cohort is mostly comprised of NHW men. In Hispanic men, statin use with or without TTh was inversely associated with aggressive PCa. Pre-diagnostic use of TTh or statins, independent or in combination, was inversely associated with aggressive PCa, including in NHW and Hispanics men, but was not with PCSM. The findings for use of statins with aggressive PCa are consistent with cohort studies. Future prospective studies are needed to explore the independent inverse association of TTh and the combined inverse association of TTh plus statins on fatal PCa.
登录
查看更多内容
影响因子:
39
作者:
Baillargeon, Jacques;Urban, Randall J.;Ottenbacher, Kenneth J.;Pierson, Karen S.;Goodwin, James S.
通讯作者:
Goodwin, James S.
影响因子:
2
作者:
Lopez DS;Advani S;Tsilidis KK;Wang R;Canfield S
通讯作者:
Canfield S
影响因子:
3.7
作者:
Finkle WD;Greenland S;Ridgeway GK;Adams JL;Frasco MA;Cook MB;Fraumeni JF Jr;Hoover RN
通讯作者:
Hoover RN
DOI:
10.1016/j.annonc.2019.09.007
发表时间:
2020-01
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
作者:
Genkinger JM;Wu K;Wang M;Albanes D;Black A;van den Brandt PA;Burke KA;Cook MB;Gapstur SM;Giles GG;Giovannucci E;Goodman GG;Goodman PJ;Håkansson N;Key TJ;Männistö S;Le Marchand L;Liao LM;MacInnis RJ;Neuhouser ML;Platz EA;Sawada N;Schenk JM;Stevens VL;Travis RC;Tsugane S;Visvanathan K;Wilkens LR;Wolk A;Smith-Warner SA
通讯作者:
Smith-Warner SA
影响因子:
5.8
作者:
Layton, J. Bradley;Li, Dongmei;Brookhart, M. Alan
通讯作者:
Brookhart, M. Alan